Compare SGMO & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGMO | BGX |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.2M | 135.2M |
| IPO Year | 2000 | 2010 |
| Metric | SGMO | BGX |
|---|---|---|
| Price | $0.18 | $10.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 27.1M | 64.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,567,000.00 | N/A |
| Revenue This Year | $107.15 | N/A |
| Revenue Next Year | $76.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 88.60 | N/A |
| 52 Week Low | $0.12 | $10.38 |
| 52 Week High | $0.77 | $12.65 |
| Indicator | SGMO | BGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 46.54 |
| Support Level | N/A | $10.78 |
| Resistance Level | $0.55 | $10.97 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 34.48 | 39.62 |
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.